Global Pertussis Vaccine Market to Grow at a CAGR of 3.8% by 2032

 


According to a newly published market research report by 24LifeSciences, global pertussis vaccine market was valued at USD 4,917 million in 2024 and is projected to reach USD 6,341 million by 2031, growing at a compound annual growth rate (CAGR) of 3.8% during the forecast period 2025-2031.

Pertussis vaccines, which protect against whooping cough caused by the Bordetella pertussis bacterium, are critical components of global immunization programs. These vaccines are available as whole-cell (wP) and more commonly used acellular (aP) formulations, with the latter offering a refined safety profile. Their established role in preventing severe respiratory illness, particularly in vulnerable infant populations, continues to underpin their public health importance and drive consistent market demand across both pediatric and adult vaccination schedules.

Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/7394/pertussis-vaccine-market

Rising Global Disease Burden and Expanding Immunization Programs Fuel Market Growth

The increasing global incidence of pertussis, particularly among adolescents and adults due to waning immunity, remains a primary growth driver for the vaccine market. Many countries experience cyclical outbreaks every three to five years, creating consistent demand for booster vaccinations and maternal immunization programs designed to protect newborns. This epidemiological pattern ensures a stable and recurring need for vaccine supplies in both developed and developing healthcare systems.

Furthermore, government policies and recommendations from global health bodies like the World Health Organization (WHO) continue to expand immunization programs. The introduction and scaling of maternal Tdap vaccination programs to prevent infant mortality have significantly boosted market growth. National immunization schedules increasingly recommend booster doses for older children, adolescents, and adults, substantially expanding the eligible vaccination population beyond traditional childhood immunization programs.

Technological Advancements in Vaccine Formulations Enhance Safety and Efficacy

Technological advancements in acellular pertussis vaccine production have transformed the market by improving product purity, safety profiles, and batch-to-batch consistency. These innovations have strengthened regulatory acceptance and enabled pharmaceutical manufacturers to scale production efficiently, supporting long-term market expansion. The shift from whole-cell to acellular vaccines represents a significant improvement in vaccine technology, addressing previous concerns about reactogenicity while maintaining protective efficacy.

Ongoing clinical research continues to explore next-generation vaccine formulations, including those that provide longer-lasting immunity and are more effective against currently circulating strains. The development of combination vaccines that include pertussis components alongside other antigens has simplified immunization schedules and improved vaccination compliance rates, further supporting market growth through enhanced product offerings.

Market Challenges: Vaccine Hesitancy and Regulatory Complexities

Despite positive growth trends, the market faces notable challenges:

  • Vaccine hesitancy and misinformation impacting vaccination coverage rates
  • Stringent regulatory approval pathways in major markets like the U.S. and Europe
  • High development costs associated with vaccine research and clinical trials
  • Complex cold chain logistics requirements for vaccine distribution

Additionally, the mature nature of pediatric vaccination markets in developed regions creates limited volume growth opportunities, shifting commercial focus to adult and booster segments that present different adoption challenges. Market saturation in some regions combined with the need for continuous investment in vaccine development creates ongoing pressure on manufacturers to innovate while maintaining affordability.

Get the Complete Report & Table of Contents: https://www.24lifesciences.com/pertussis-vaccine-market-739

Europe Leads the Global Pertussis Vaccine Market

The European region dominates the global pertussis vaccine market, accounting for the largest market share. This leadership position is driven by:

  • Well-established and comprehensive national immunization programs
  • High vaccination coverage rates supported by robust healthcare infrastructure
  • Strong regulatory frameworks and government support for vaccination
  • Advanced healthcare systems with high awareness of preventive medicine

North America represents a significant secondary market, characterized by sophisticated vaccination programs and high adoption rates of acellular pertussis vaccines. The region benefits from strong recommendations by health authorities and well-funded public health initiatives that ensure consistent vaccine demand across all age groups.

Combination Vaccines Dominate Market by Product Type

By product type, combination vaccines incorporating pertussis components represent the dominant segment due to their ability to simplify immunization schedules and improve compliance. These vaccines, particularly DTaP formulations for children and Tdap formulations for adolescents and adults, offer comprehensive protection against multiple diseases in a single injection, making them highly favored by healthcare providers and public health programs.

By end user, public immunization programs constitute the largest segment, as they are the primary channel for vaccine distribution globally. Governments and international health organizations procure substantial quantities of vaccines to implement national childhood immunization schedules, ensuring broad population coverage and creating predictable, large-scale demand for manufacturers.

Competitive Landscape: Highly Consolidated with Global Leaders

Global pertussis vaccine market is highly consolidated, with the top two manufacturers collectively holding a dominant market share. The competitive environment is shaped by manufacturing capabilities, regulatory compliance, product portfolios, and distribution networks that ensure reliable vaccine supply to global markets.

Key companies profiled in the report include:

  • Sanofi Pasteur
  • GSK
  • Mitsubishi Tanabe Pharma
  • Wuhan Institute of Biological Products
  • Walvax Biotechnology
  • KM Biologics
  • and More

Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/pertussis-vaccine-market-7394

Market Opportunities: Emerging Economies and Innovation

Significant growth opportunities exist in emerging markets across Asia-Pacific, Latin America, and Africa, supported by improving healthcare access, rising awareness of vaccine-preventable diseases, and support from international organizations. These regions present substantial addressable markets as they strengthen their immunization programs and healthcare infrastructure.

Furthermore, the ongoing development of novel vaccine formulations, including those with improved safety profiles, longer duration of protection, and alternative delivery systems, is expected to generate new intellectual property and expand clinical adoption. The growing recognition of the need for lifelong pertussis immunization creates additional opportunities in the adolescent and adult vaccination segments.

Access the Full Report

Download a Free Sample Report (PDF):
https://www.24lifesciences.com/download-sample/7394/pertussis-vaccine-market

Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/pertussis-vaccine-market-7394

About 24LifeSciences

24LifeSciencesis a leading provider of market intelligence and strategic research reports across pharmaceuticals, biotechnology, medical devices, and healthcare technologies. Our reports are designed to support data-driven decision-making for manufacturers, healthcare providers, investors, consultants, and policy makers worldwide.

Follow us on LinkedIn:
https://www.linkedin.com/company/lifesciences24/

 

Comments

Post a Comment

Popular posts from this blog

Mechanical Rubber Tracks Market Growth Analysis, Market Dynamics, Key Players and Innovations, Outlook and Forecast 2025-2031

Mechanical rubber tracks, also referred to as rubber track pads or rubber belting, are robust traction surfaces used on heavy equipment and vehicles. These tracks are manufactured using high-strength rubber compounds designed to deliver optimal traction and support on various terrains, including soft soil, mud, snow, and ice. They are often utilized as a substitute for traditional steel tracks on equipment such as bulldozers, excavators, and military vehicles. Mechanical rubber tracks provide numerous advantages, including reduced ground pressure, enhanced mobility, and quieter operations compared to steel tracks. Get free sample of this report at :  https://www.intelmarketresearch.com/download-free-sample/529/mechanical-rubber-tracks-market  Market Size In 2024, the global market for Mechanical Rubber Tracks was valued at USD 2,163.82 million, reflecting significant growth from USD 1,541.86 million in 2020. The market is projected to grow at a compound annual growth rate (CAG...
Read more

Nitrogen Localized Cryotherapy Machine Market Forecast 2026: Revenue Insights

Image
  According to a newly published market research report by 24LifeSciences , the global nitrogen localized cryotherapy machine market was valued at USD 102.4 million in 2024  and is projected to reach USD 185.6 million by 2032 , growing at a compound annual growth rate (CAGR) of 7.4% during the forecast period 2025–2032 . Nitrogen localized cryotherapy machines represent advanced medical and wellness devices engineered for the highly precise application of extremely cold liquid nitrogen vapor to targeted body areas. This non-invasive therapeutic approach induces rapid localized vasoconstriction followed by vasodilation, effectively reducing inflammation, alleviating pain, and accelerating muscle recovery through enhanced blood flow to treated tissues. Distinct from whole-body cryotherapy systems, these devices focus treatment specifically on injury sites or aesthetic zones, providing practitioners with unparalleled control and patients with targeted therapeutic benefits. Down...
Read more

2-Methoxyestradiol Reagent Market to Reach USD 10.8 Billion by 2032 | CAGR 10.8%

Image
  According to a newly published market research report by 24LifeSciences , global 2-Methoxyestradiol Reagent market was valued at USD 113 million in 2024  and is projected to reach USD 232 million by 2031 , growing at a compound annual growth rate (CAGR) of 10.8% during the forecast period 20252031 . 2-Methoxyestradiol, a naturally occurring metabolite of estradiol, has gained significant importance in biomedical research due to its demonstrated anti-cancer properties and unique mechanism of action. As an endogenous compound that inhibits microtubule assembly and demonstrates anti-angiogenic effects, this reagent has become indispensable for researchers studying cancer therapeutics, cellular pathways, and drug development processes. Its established role in disrupting cancer cell proliferation continues to underpin its critical position in modern molecular biology and pharmaceutical research. Download a Free Sample Report (PDF):  https://www.24lifesciences.com/download-...
Read more